Delving into the Latest Updates on Atorvastatin strontium with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Atorvastatin, 阿托伐他汀, Newvast

Target

HMGCR

Action

inhibitors

Mechanism

HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Hyperlipidemias

Inactive Indication-

Originator Organization

Hanmi Pharmaceutical Co., Ltd.

Active Organization

Hanmi Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization

Viatris Pharmaceutical GK

Astellas Pharma, Inc.

Drug Highest PhaseApproved

First Approval Date

South Korea (28 Nov 2008),

Hyperlipidemias

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC66H70F2N4O10Sr

InChIKeyDTKMQPSVRFQLOA-MNSAWQCASA-N

CAS Registry1072903-92-4

Two Dutch guidelines (Stroke and Cardiovascular Risk Management) provide conflicting advice on optimal statin treatment in older patients. In the SAFEST - RCT, the investigators will assess the impact of starting versus not starting a statin in frail individuals aged 70 and above with a recent ischemic stroke or transient ischemic attack (TIA) on their health-related quality of life and Major Adverse Cardiovascular Events (MACE) free survival during a two-year follow-up period.

Start Date01 Feb 2025

Sponsor / Collaborator

University of Amsterdam

TCTR20241030002

/ Not yet recruitingPhase 1IIT

Bioequivalence study of a randomized, open-label, single oral dose, 4-period, 2-treatment, 2-sequence, full replicate, crossover study of Atorvastatin 80 mg tablets relative to Lipitor 80 mg tablets in healthy Thai volunteers under fasting condition

Start Date13 Jan 2025

Sponsor / Collaborator

Bio-innova Co., Ltd

IRCT20240807062680N1

/ CompletedNot ApplicableIIT

Dose-Dependent Anti-Inflammatory Effects of Atorvastatin as Adjunctive Therapy for Seizure Control in Drug-Resistant Epilepsy

Start Date23 Dec 2024

Sponsor / Collaborator

Tehran University of Medical Sciences

100 Clinical Results associated with Atorvastatin strontium

Login to view more data

100 Translational Medicine associated with Atorvastatin strontium

Login to view more data

100 Patents (Medical) associated with Atorvastatin strontium

Login to view more data

13,587

Literatures (Medical) associated with Atorvastatin strontium

31 Dec 2025·Pulmonology

Early effects of acetazolamide on hemoglobin mass and plasma volume in chronic mountain sickness at 5100 m

Article

Author: Salazar-Granara, A.A. ; Doutreleau, S. ; Verges, S. ; Pina, A. ; Guergour, D. ; Connes, P. ; Pichon, A. ; Hancco, I. ; Champigneulle, B. ; Howe, C.A. ; Robach, P. ; Stauffer, E. ; Brugniaux, J.V.

INTRODUCTION AND OBJECTIVES:

Chronic Mountain Sickness (CMS) syndrome, combining excessive erythrocytosis and clinical symptoms in highlanders, remains a public health concern in high-altitude areas, especially in the Andes, with limited therapeutic approaches. The objectives of this study were to assess in CMS-highlanders permanently living in La Rinconada (5100-5300 m, Peru, the highest city in the world), the early efficacy of acetazolamide (ACZ) and atorvastatin to reduce hematocrit (Hct), as well as the underlying mechanisms focusing on intravascular volumes.

MATERIALS AND METHODS:

Forty-one males (46±8 years of age) permanently living in La Rinconada for 15 [10-20] years and suffering from CMS were randomized between ACZ (250 mg once-daily; N = 13), atorvastatin (20 mg once-daily; N = 14) or placebo (N = 14) uptake in a double-blinded parallel study. Hematocrit (primary endpoint) as well as arterial blood gasses, total hemoglobin mass (Hb_mass) and intravascular volumes were assessed at baseline and after a mean (±SD) treatment duration of 19±2 days.

RESULTS:

ACZ increased PaO₂ by +13.4% (95% CI: 4.3 to 22.5%) and decreased Hct by -5.2% (95% CI: -8.3 to -2.2%), whereas Hct remained unchanged with placebo or atorvastatin. ACZ tended to decrease Hb_mass (-2.6%, 95% CI: -5.7 to 0.5%), decreased total red blood cell volume (RBCV, -5.3%, 95% CI: -10.3 to -0.3%) and increased plasma volume (PV, +17.6%, 95% CI: 4.9 to 30.3%). Atorvastatin had no effect on intravascular volumes, while Hb_mass and RBCV increased in the placebo group (+6.1%, 95% CI: 4.2 to 7.9% and +7.0%, 95%CI: 2.7 to 11.4%, respectively).

CONCLUSIONS:

Short-term ACZ uptake was effective to reduce Hct in CMS-highlanders living at extreme altitude >5,000 m and was associated with both an increase in PV and a reduction in RBCV.

31 Dec 2025·Virulence

Disruption of CmHmgr1 triggers apoptosis and causes defects in growth, conidiogenesis, and mycoparasitism of Coniothyrium minitans

Article

Author: Hu, Zijin ; Yang, Xiaoxiang ; Zhang, Zhongmei ; Wang, Haixuan ; Jiang, Daohong ; Zhang, Lei ; Fu, Yanping

Coniothyrium minitans is a well-known mycoparasite against Sclerotinia sclerotiorum. Two critical factors for the commercialization of C. minitans as a biocontrol agent are conidial production and parasitism. To decipher the mechanisms of conidiogenesis and mycoparasitism in C. minitans, a conidiation-deficient mutant, ZS-1TN5012, was isolated from a transfer DNA (T-DNA) insertional library. This mutant exhibited significantly reduced hyphal development, poor conidiation, and decreased sclerotial mycoparasitism. CmHmgr1 encoding a 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) was disrupted by the T-DNA insertion. The colony morphology of the wild-type strain ZS-1 resembled that of the mutant ZS-1TN5012 when the HMGR inhibitor atorvastatin was added to potato dextrose agar, with the mutant showing more sensitivity to atorvastatin. Furthermore, cellular localization assays revealed that CmHmgr1 was localized in mitochondria. Gene replacement and complementation experiments confirmed that CmHmgr1 is involved in the growth, conidiogenesis and mycoparasitism of C. minitans, and disruption of CmHmgr1 triggers apoptosis.

31 Dec 2025·PHARMACEUTICAL BIOLOGY

Yiqi Wenyang decoction protects against the development of atherosclerosis by inhibiting vascular inflammation

Article

Author: Zhang, Shujie ; Huang, Zhe ; Zhang, Han ; Shiu, Chiwen ; Sun, Lingling ; Yan, Xingqun ; Hua, Shuang ; Zhu, Yao ; Gu, Ping ; Jiang, Weimin

CONTEXT:

Vascular inflammation is a key process in the pathogenesis of atherosclerosis, which is regulated by NF-κB pathway. Yiqi Wenyang decoction (YQWY), a Traditional Chinese medicine (TCM) formula, has anti-inflammatory properties and may inhibit this pathway, potentially offering anti-atherosclerotic effects.

OBJECTIVE:

The purpose of this study is to investigate the effects of YQWY on atherosclerosis and the underlying mechanism. Materials and methods: ApoE^-/- mice were fed a Western diet and administered with YQWY (low or high dose), atorvastatin, or vehicle for 13 weeks. The size of atherosclerotic plaques was assessed using ORO staining. Vascular inflammation was evaluated with IF or IHC staining. The mechanisms and signaling pathways underlying the effect of YQWY on vasculature were studied using transcriptomic analysis and were validated in vitro in endothelial cells and macrophages.

RESULTS:

YQWY attenuated atherosclerotic plaque development which was associated with reduced vascular inflammation as demonstrated by transcriptomic analysis of aorta. This was verified by reduced expression of proinflammatory chemokines, adhesion molecules, and inflammatory cytokines in aortas from YQWY-treated mice at both mRNA and protein levels. Mechanistically, YQWY suppressed NF-κB activation in endothelial cells and, to a lesser extent, macrophages possibly.

DISCUSSION AND CONCLUSIONS:

YQWY protects against vascular inflammation and atherosclerosis by suppressing NF-κB pathway, suggesting the potential of YQWY and its active ingredients as novel anti-atherosclerotic therapeutics.

12

News (Medical) associated with Atorvastatin strontium

04 Aug 2025

·pharma.economictimes.indiatimes.com

NPPA sets retail prices of 37 drugs; notifies 4 scheduled formulations ceiling price

New Delhi: India’s drug price controller, NPPA has fixed the retail prices of 37 new drug including key type-2 diabetes formulations, antibiotics, cardiac therapies among several others. Issuing a gazette notification, the National Pharmaceutical Pricing Authority (NPPA) announced that the based on the decision of the 135th Authority meeting, the body has fixed retail prices of 37 formulations under Drugs (Prices Control) Order, 2013.” The notified list of 37 formulations includes key diabetes formulations of Empagliflozin, Sitagliptin, Meformin and Linagliptin. Additionally the list comprises formulation of Atorvastatin & Ezetimibe indicated for the treatment of high cholesterol and fats. The list further lunches other common anti-inflammatory formulations and drugs like Paracetamol, Diclofenac among several others. Under the Drugs Price Control Order any marketer, or manufacturers that intends to market a new drug in India is required to obtain a prior approval of the particular drug retail price from the NPPA and in case the fixed price is not complied, then the concerned manufacturer/marketing company is required to deposit the overcharged amount along with an interests per the relevant provision. However, the fixed retail prices are applicable only to the individual manufacturer / marketer who have applied for the same and are specified in the mentioned in the notified list. Meanwhile, in a separate gazette notification the national drug price controller has fixed the ceiling price of four scheduled formulations. The latest notified list includes Ipratropium, Sodium nitroprusside, Povidone iodine, and Diltiazem. Ipratropium is a ‘respirator solution’ indicated for the treatment of condictions like COPD and the drug ceiling price is capped at ₹2.96 per unit. Sodium nitroprusside is an injectable used to control high blood pressure and ceiling price of the formulation is fixed at ₹28.99. The other two scheduled formulations Povidone iodine and Diltiazem are used to treat skin infections and angina (severe chest pain), and the their ceiling price is fixed at ₹6.26 per ml and ₹26.72 per capsule respectively. According to the Ministry of Health and Family Welfare , the National list of Essential Medicines includes those formulations which are indicated for the treatment of diseases which is a public health problem in India, recommended under National Health Programs of India and several other factors. The prices of drugs categorised in the list are fixed and maintained by the NPPA to ensure the affordability of essential drugs for consumers and currently the list includes over 900 formulations. By Online Bureau ,

NDA

04 Aug 2025

·pharma.economictimes.indiatimes.com

NPPA sets retail prices of 37 drugs; notifies 4 scheduled formulations ceiling price

New Delhi: India’s drug price controller, NPPA has fixed the retail prices of 37 new drug including key type-2 diabetes formulations, antibiotics, cardiac therapies among several others. Issuing a gazette notification, the National Pharmaceutical Pricing Authority (NPPA) announced that the based on the decision of the 135th Authority meeting, the body has fixed retail prices of 37 formulations under Drugs (Prices Control) Order, 2013.” The notified list of 37 formulations includes key diabetes formulations of Empagliflozin, Sitagliptin, Meformin and Linagliptin. Additionally the list comprises formulation of Atorvastatin & Ezetimibe indicated for the treatment of high cholesterol and fats. The list further lunches other common anti-inflammatory formulations and drugs like Paracetamol, Diclofenac among several others. Under the Drugs Price Control Order any marketer, or manufacturers that intends to market a new drug in India is required to obtain a prior approval of the particular drug retail price from the NPPA and in case the fixed price is not complied, then the concerned manufacturer/marketing company is required to deposit the overcharged amount along with an interests per the relevant provision. However, the fixed retail prices are applicable only to the individual manufacturer / marketer who have applied for the same and are specified in the mentioned in the notified list. Meanwhile, in a separate gazette notification the national drug price controller has fixed the ceiling price of four scheduled formulations. The latest notified list includes Ipratropium, Sodium nitroprusside, Povidone iodine, and Diltiazem. Ipratropium is a ‘respirator solution’ indicated for the treatment of condictions like COPD and the drug ceiling price is capped at ₹2.96 per unit. Sodium nitroprusside is an injectable used to control high blood pressure and ceiling price of the formulation is fixed at ₹28.99. The other two scheduled formulations Povidone iodine and Diltiazem are used to treat skin infections and angina (severe chest pain), and the their ceiling price is fixed at ₹6.26 per ml and ₹26.72 per capsule respectively. According to the Ministry of Health and Family Welfare , the National list of Essential Medicines includes those formulations which are indicated for the treatment of diseases which is a public health problem in India, recommended under National Health Programs of India and several other factors. The prices of drugs categorised in the list are fixed and maintained by the NPPA to ensure the affordability of essential drugs for consumers and currently the list includes over 900 formulations. By Online Bureau ,

NDA

23 May 2025

·pharma.economictimes.indiatimes.com

Alembic secures USFDA nod for Amlodipine and Atorvastatin Tablets

Mumbai: Alembic Pharmaceuticals Limited today announced it has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Amlodipine and Atorvastatin Tablets USP, in multiple strengths. The approved product is therapeutically equivalent to Pharmacia and Upjohn Co. LLC’s reference-listed drug (RLD), Caduet Tablets . The drug, available in strengths ranging from 2.5 mg/10 mg to 10 mg/80 mg, are indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. With this approval, Alembic now has a cumulative total of 223 ANDA approvals from the USFDA, comprising 199 final approvals and 24 tentative approvals. By Online Bureau ,

Drug ApprovalNDA

100 Deals associated with Atorvastatin strontium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Atorvastatin strontium	C10BA05	DB01076

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hyperlipidemias	South Korea	Hanmi Pharmaceutical Co., Ltd.	28 Nov 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


23-PUB (ADA2024)	Phase 3	Diabetes Mellitus, Type 2 \| Dyslipidemias	65	Atorvastatin/Fenofibrate 20 mg/160 mg	seoyqnabwu(vwbiravqgs) = dxanpifmud iqrkhhatpl (fcyomoncjo, 145.3)	Positive	14 Jun 2024
				Atorvastatin 20 mg	seoyqnabwu(vwbiravqgs) = nmyjnhxnbp iqrkhhatpl (fcyomoncjo, 75.7)
ADA2024	Not Applicable	Angina Pectoris	-	High-intensity Atorvastatin	ptnuahtvrr(etkecqlnts): aHR = 0.82 (95% CI, 0.67 - 1.01), P-Value = 0.066 View more	-	14 Jun 2024
				Moderate-intensity Atorvastatin + Ezetimibe
NCT01341730 (PIONEER, CTgov)	Phase 4	Coronary Artery Disease \| Angina, Unstable \| Carotid Artery Diseases ... View more	41	Atorvastatin 20mg (Atorvastatin 20 mg)	rdkkvkulja(zjwoznxnox) = jxdwhrynyw shmascwbee (rnkrxmdnyq, 0.04) View more	-	06 Aug 2020
				Pioglitazone+Atorvastatin (Atorvastatin 20 mg + Pioglitazone 30 mg)	rdkkvkulja(zjwoznxnox) = btbbrujkkl shmascwbee (rnkrxmdnyq, 0.07) View more
4D Study (ASN2013)	Not Applicable	Diabetes Mellitus	1,255	Atorvastatin 20 mg	bxeinnjgna(xpospplavv) = No case of rhabdomyolysis was reported mlsahimzux (umalzyxjmd ) View more	Negative	05 Nov 2013
				Placebo
Tandem Meetings ASTCT and CIBMTR2013	Phase 2	Hematopoietic stem cell transplantation	14	Atorvastatin 40 mg	qfjgtbswdb(xxpdlcpbmd) = eawlgzkgab vcrknuinjw (yakeqxdtyu ) View more	-	01 Feb 2013
ASCO_GU2012	Phase 2	-	14	Atorvastatin 20 mg	zukybyujao(kpndrilvfl) = revpyokmjy hhhxvogege (icjotujpsx )	-	10 Feb 2012
				Celecoxib 200 mg	zukybyujao(kpndrilvfl) = xdddvhktfa hhhxvogege (icjotujpsx )
EULAR2011	Phase 2	Rheumatoid Arthritis	111	Tofacitinib 10 mg BID	cbhzvawbyj(iuahscusgl) = uajvfydtvn mzkfbsfthy (hcyjjvwutf ) View more	Positive	25 May 2011
				Atorvastatin 10 mg QD	cbhzvawbyj(iuahscusgl) = wlwkwnjsug mzkfbsfthy (hcyjjvwutf ) View more
Atorvastatin in Patients with Low Grade or Refractory Non-Hodgkin's Lymphoma (ASCO2009)	Phase 2	Non-Hodgkin's lymphoma refractory	14	Atorvastatin 80 mg	yfshceyaac(icyxdcfshw) = fxklqspxqc pdsrttfhiy (wianmzyuwm )	-	20 May 2009
NCT00435045 (CTgov)	Phase 3	Hypertriglyceridemia	245	Atorvastatin+Lovaza(Omacor) (Lovaza(Omacor) + Atorvastatin)	ewsispcpks(qhmowqxjaw) = nqhbtcloto fkgmseovid (uinvaddtft, giyeymvqve - jgwlbxdkys) View more	-	12 May 2009
				Placebo+Atorvastatin (Placebo + Atorvastatin)	ewsispcpks(qhmowqxjaw) = bgblgquaki fkgmseovid (uinvaddtft, unnbkhulqy - denrpjvcyj) View more
ASCO2008	Phase 2	Recurrent Prostate Carcinoma	8	Atorvastatin 20mg/day	nmraimjtme(bkxnwwmknz) = rxkcfvbrrh tgmrmhmlan (pfjzzzowga ) View more	Negative	20 May 2008